Available Trials

Main Content


For more information regarding these studies, contact Cancer Research & Registry at (601) 984-1095

ASN002-101: A Phase 1/2, Open-Label, Uncontrolled, Multidose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors

This study is for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), Follicular Lymphoma (FL), Mantel Cell Lymphoma (MCL) or Advanced Solid Tumors (Part A only). The purpose of this study is to find the safest dose of ASN002, and to see if it has any effects against certain cancers.

Cancer cells can cause uncontrollable cell growth. Studies have shown that blocking certain enzymes called Spleen Tyrosine kinase (SYK) and Janus kinase (JAK) can slow or stop cancer growth.

Principal Investigator: Stephanie Elkins, MD

Non Hodgkin’s Lymphoma

Bayer CHRONOS-4: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) 

The purpose of the 17833 study is to assess whether the drug being tested (copanlisib) in combination with standard immunochemotherapy (rituximab in combination with bendamustine [R-B] and rituximab in combination with a 4 drug combination of cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone [R-CHOP])  is effective and safe compared with placebo (simulated treatment) in combination with standard immunochemotherapy (R-B or R-CHOP) in participants with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) who have received one but no more than 3 lines of treatment and have been previously exposed to rituximab and alkylating agent.

Participants should be in need of, and fit for, immunochemotherapy and should not be resistant to rituximab (resistance defined as lack of response, or progression within 6 months of the last course of treatment with a rituximab containing regimen). The study is composed of 2 parts: a safety run-in, where the recommended phase III dose of copanlisib in combination with R-CHOP will be determined and a phase III part for the copanlisib R-B combination   From the RB safety run-in part of the study that has already completed, the recommended dose of copanlisib was determined at 60 mg.  This dose was reviewed and agreed by an independent Data Monitoring Committee, who also reviews the safety data that is collected during the study.

Principal Investigator: Stephanie Elkins, MD